Influence of Hepatitis C Virus and *IL28B* Genotypes on Liver Stiffness

Lene Fogt Lundbo[1,2,3]*, **Louise Nygaard Clausen**[1,2,3], **Nina Weis**[1,3], **Kristian Schønning**[3,4], **Lene Rosenørn**[1], **Thomas Benfield**[1,2,3], **Peer Brehm Christensen**[5]

1. Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, **2.** Clinical Research Centre, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, **3.** Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, **4.** Department of Clinical Microbiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, **5.** Department of Infectious Diseases, Odense University Hospital, Odense, Denmark

*lene.lundbo@gmail.com

Abstract

Objective: Liver fibrosis has been associated with hepatitis C virus (HCV) genotype and genetic variation near the interleukin 28B (*IL28B*) gene, but the relative contribution is unknown. We aimed to investigate the relation between HCV genotypes, *IL28B* and development of liver stiffness.

Patients and Methods: This cross-sectional study consists of 369 patients with chronic hepatitis C (CHC). Liver stiffness was evaluated using transient elastograhy (TE). Factors associated with development of liver fibrosis were identified by logistic regression analysis.

Results: We identified 369 patients with CHC. 235 were male, 297 Caucasians, and 223 had been exposed to HCV through intravenous drug use. The overall median TE value was 7.4 kPa (interquartile range (IQR) 5.7–12.1). HCV replication was enhanced in patients carrying the *IL28B* CC genotype compared to TT and TC (5.8 vs. 5.4 $\log_{10}$ IU/mL, p=0.03). Patients infected with HCV genotype 3 had significantly higher TE values (8.2 kPa; IQR, 5.9–14.5) compared to genotype 1 (6.9 kPa; IQR, 5.4–10.9) and 2 (6.7 kPa; IQR, 4.9–8.8) (p=0.02). Within patients with genotype 3, *IL28B* CC genotype had the highest TE values (p=0.04). However, in multivariate logistic regression, using various cut-off values for fibrosis and cirrhosis, only increasing age (odds ratio (OR) 1.09 (95% confidence interval (CI), 1.05–1.14 per year increment)), ALT (OR 1.01 (95% CI, 1.002–1.011), per unit increment) and HCV genotype 3 compared to genotype 1 (OR 2.40 (95% CI, 1.19–4.81), were consistently associated with cirrhosis (TE>17.1 kPa).

Conclusions: Age, ALT and infection with HCV genotype 3 were associated with cirrhosis assessed by TE. However, *IL28B* genotype was not an independent predictor of fibrosis in our study.

Introduction

It is estimated that about 170 million people are infected with hepatitis C virus (HCV) world-wide, and that more than 350.000 people die annually from chronic hepatitis C (CHC) related end-stage liver disease [1].

The influence of HCV genotypes in development of liver fibrosis is not well established. There are 6 epidemiologically important genotypes. In Denmark, genotypes 1 and 3 predominate [2]. Numerous subtypes (e.g., subtypes 1a and 1b within genotype 1 and subtypes 3a and 3b within genotype 3) exist. HCV genotype 1 has been associated with higher mortality, AIDS in HIV/HCV coinfected, and hepatocellular carcinoma [3–5], whereas HCV genotype 3 has been associated with development of hepatic steatosis, fibrosis and progression to cirrhosis in some, but not all, studies [6–10].

Several genome-wide association studies have revealed that the *IL28B* single-nucleotide polymorphism (SNP), rs12979860 genotype CC is advantageous in predicting the probability of spontaneous clearance and sustained virologic response following pegylated-interferon and ribavirin treatment in genotype 1 infected patients [11–13].

Recent publications of both HCV monoinfected and HIV-HCV coinfected patients, have studied the role of *IL28B* and the development of liver steatosis and fibrosis. Using transient elastography (TE), Barreiro et al. reported an association of the CC genotype to liver fibrosis in coinfected individuals whereas Marabita et al. did not show any association as assessed by liver biopsy in monoinfected individuals [14, 15]. Ydreborg et al. and Rembeck et al. found an association between the CC genotype and more pronounced liver histopathology in HCV genotype 3 infection [16, 17]. Noureddin et al. was unable to show a difference in the frequency of fibrosis progression between patients with *IL28B* CC and non-CC genotypes but the *IL28B* CC genotype was associated with hepatic necro-inflammation, higher alanine aminotransferase (ALT) levels, and worse clinical outcomes [18]. Similarly, two studies of steatosis came to conflicting results [19, 20].

We aimed to investigate the relation between HCV genotypes and *IL28B* and development of liver fibrosis, assessed by TE, in patients infected with HCV.

Patients and Methods

Study population

This observational, retrospective study consisted of two independent cohorts of patients with CHC, seen consequetively in Department of Infectious Diseases, Odense University Hospital (OUH) or Department of Infectious Diseases, Hvidovre Hospital (HH) with a TE performed between March 2007 and December 2012. Inclusion criteria were HCV antibody positivity and one positive serum HCV RNA followed by a valid TE. All patients had a positive HCV antibody measurement prior to TE. Exclusion criteria were HCV treatment within 6 months prior to TE, any other cause of liver disease, hepatitis B virus and HIV infection. Demographic, clinical and laboratory parameters were collected from medical records by a physician.

According to Danish Legislation, the Research Ethics Committee can grant an exemption from obtaining informed consent for research projects based on biological material under certain circumstances, and for this study such an exemption was granted.

The study was approved by the Danish Data Protection Agency (record no. 2012-231-0031).

Laboratory

Participants were diagnosed with HCV infection on the basis of anti-HCV detected in a serum or plasma sample by 3rd generation enzyme-linked immunosorbent assay and confirmed by recombinant immunoplot assay or HCV RNA [21, 22]. All samples were tested for RNA levels in the real-time polymerase chain reaction (PCR) system COBAS AmpliPrep/COBAS TaqMan HCV (CAP/CTM HCV) [23]; the detection limit was 15 IU/ml.

HCV genotype was determined with genotype specific primers from the 5' noncoding region of the virus by RT-PCR [24] or by sequence analysis of RT-PCR generated fragments using C/E1 and NS5B-specific primers [25, 26].

IL28B genotyping

For patients from HH genotyping of the *IL28B* rs12979860 SNP (hereafter refered to as the *IL28B* SNP) were performed by LGC Genomics (Herts, United Lingdom) using a KASP competitive allele-specific PCR [27]. For a minority, genotypings were done by Molecular Genetics, Department of Clinical Biochemistry Department, Copenhagen University Hospital. Patients at OUH were tested by a SNP genotyping assay using real-time PCR(Lifetechnologies).

Transient Elastography

TE was determined by Fibroscan (EchoSens, Paris, France) and was considered successfull if 10 valid measurements were obtained (valid measurements >60% and interquartile range <25%). TE was expressed in kilopascal (kPa) [28]. Cut-off

values for liver stiffness and different degrees of fibrosis were assessed by two methods. Firstly, advanced liver fibrosis was defined as a TE value >9.5 kPa [29, 30]. Secondly, recent simplified cut-off values were used: no fibrosis: ≤7.0 kPa; fibrosis: 7.1–17.1 kPa; and cirrhosis: >17.1 kPa [31].

Statistical analysis

Values are expressed as median, IQR and percent. Differences were compared using the Kruskal-Wallis test or the Wilcoxon Signed Rank Test for continuous variables and for categorical variables using X^2 or Fisher's exact test, as appropriate. Logistic regression analyses using TE cut-off defined above were performed to evaluate predictors of fibrosis after adjusting for age, HCV genotype and *IL28B* genotypes and results were presented as OR with 95% CI. Genotype equilibrium was tested by the method of Hardy and Weinberg [32]. All statistical analyses were performed using Statistical Analysis Systems (SAS version 9.3; SAS Institute, Cary, NC, USA) or IBM SPSS Statistics (version 20; IBM, Armonk, New York, USA).

Results

Patient characteristics

The study included 369 patients; 230 patients from OUH and 139 from HH. The majority of these were male (64%; 95%CI, 59–69%), Caucasians (80%; 95% CI, 76–85%), and had been exposed to HCV through injection drug use (IDU) (60%; 95% CI, 55–65%). The median time of known HCV seropositivity was 26.3 (IQR, 3.2–96.9) months and the median age was 48 (IQR, 39–54) years at the time of TE. For all HH patients ALT was obtained within a 182 days time range relative to the fibroscan. For forty-three of the OUH patients ALT was not provided within 6 months prior to or after the fibroscan. The first obtained HCV RNA was available for all patients. HCV RNA within a 180 days range from the TE was available for 218 patients (135 HH patients and 83 OUH patients). No statistical significant difference was observed between the two RNA values (p=0.09).

The majority of the patients were infected with HCV genotype 1 (50%; 95% CI, 45–55%), followed by genotype 3 (40%; 95% CI, 35–45%) and genotype 2 (9%; 95% CI, 7–13%). Only 8 patients were infected with genotype 4 and these patients were not considered further.

There was no difference in sex, route of exposure or known duration of infection according to HCV genotype, but patients infected with genotype 3 were younger (p=0.001) than patients infected with genotype 1 or 2. Genotype 1 was more frequent among Caucasians (p=0.03). The main characteristics of the study population are depicted in Table 1. The patients were either hepatitis C treatment naïve at the time of - or had relapsed at least 6 months prior to - the TE. Fourteen patients had been treated prior to their TE.

Table 1. Patient characteristics for 369 patients with chronic hepatitis C virus infection by HCV genotype.

	Genotype 1	Genotype 2	Genotype 3	Total	p-value
	n (%)	n (%)	n (%)	n	
	185 (50)	35 (10)	149 (40)	n=369	
Sex					0.28**
Male	120 (65)	18 (51)	97 (65)	235 (64)	
Female	65 (35)	17 (49)	52 (35)	134 (36)	
Age at TE, years	49 (37–55)	54 (46–57)	46 (38–53)	48 (39–54)	0.001***
Race					0.03**
Caucasian	159 (86)	26 (74)	112 (75)	297 (80)	
Non-Caucasian/unknown	26 (14)	9 (26)	37 (25)	72 (20)	
Route of exposure					0.17**
Injection drug use	109 (59)	17 (49)	97 (65)	223 (60)	
Other/unknown	76 (41)	18 (51)	52 (35)	146 (40)	
Length of known HCV infection, months	18.8 (2.8–86.1)	45.6 (2.9–107.4)	36.1 (3.9–104.1)	26.3 (3.2–96.9)	0.27***
Previously received antiviral treatment‡					0.50**
Yes	40 (22)	6 (17)	38 (26)	84 (23)	
No	145 (78)	29 (83)	111 (75)	285 (77)	
HCV RNA, $\log_{10}$ IU/mL	5.9 (5.1–6.5)	5.5 (4.7–5.7)	5.5 (4.7–5.8)	5.6 (4.9–6.2)	0.003***
ALT, U/L	63 (38–94)	47 (26–96)	71 (42–147)	64 (38–111)	0.01***
Liver stiffness, kPa	6.9 (5.4–10.9)	6.7 (4.9–8.8)	8.2 (5.9–14.5)	7.4 (5.7–12.1)	0.02***
Liver stiffness stage					0.15**
No fibrosis (≤7.1 kPa)	95 (51)	20 (57)	65 (44)	180 (49)	
Fibrosis (7.1–17.1 kPa)	66 (36)	12 (34)	52 (35)	130 (35)	
Cirrhosis (>17.1 kPa)	24 (13)	3 (9)	32 (25)	59 (16)	
IL28B *genotype*†					0.0005*
CC	48 (27)	19 (56)	62 (45)	129 (37)	
CT	106 (60)	10 (29)	67 (48)	183 (52)	
TT	23 (13)	5 (15)	10 (7)	38 (11)	

TE, transient elastography.
*Fisher's exact test, **x^2 or ***kruskall-wallis applied as appropriate.
†rs12979860.
‡Relapsed more than 6 months prior to TE or treatment initiated after TE. All continous variabels reported as median and interquartile range

doi:10.1371/journal.pone.0115882.t001

At HH, more patients were infected with HCV through IDU compared to OUH (69% vs 58% p=0.03), and the patients from HH were older (50 years (IQR 42–55) vs. 46 years (IQR 36–53), p=0.0008). There was no difference in sex, race, frequency of HCV genotypes and *IL28B* genotypes between the two cohorts.

Viral load

Homozygous CC carriers had a significantly higher (first obtained) viral load compared to TC and TT carriers (median 5.8 and 5.4 $\log_{10}$ IU/mL, p=0.03).

The HCV genotype 2 and 3 infected homozygous CC carriers had a higher (first obtained) median HCV RNA compared to CT and TT combined (median 5.6 vs.

5.1 log₁₀ IU/mL for genotype 2 and 5.6 vs. 5.0 log₁₀ IU/mL for genotype 3). This significant difference was not observed among the genotype 1 infected patients.

HCV genotype 1 infected patients had significantly higher viral load compared to genotype 2 and 3 infected at the time of TE (table 1).

IL28B rs12979860

The majority of our study cohort (350 of 369 (95%)) was genotyped for the *IL28B* SNP. We lacked DNA to genotype the remaining 19 patients. The overall distribution of the alleles was as follows (no. of patients, %): CC (129, 37%), CT (183, 52%), TT (38, 11%). The allele distribution was in Hardy-Weinberg disequilibrium ($p < 0.05$). *IL28B* genotype differed according to HCV genotype. Genotype CC was less frequent among genotype 1 infected patients compared to genotype 2 and 3, and consequently CT and TT (non-CC) were more frequent ($P < 0.005$) (Table 1). Because prior studies have shown that *IL28B* allelic traits behave as an autosomal recessive inheritance [14] and due to the very few cases of TT, the CT and TT genotypes were combined in regression analyses (see below).

No association was found between ALT and *IL28B* genotypes.

Liver stiffness

The overall TE value was 7.4 (IQR, 5.7–12.1) kPa. Patients infected with HCV genotype 3 had significantly higher TE values (8.2 kPa; IQR, 5.9–14.5) compared to genotype 1 (6.9 kPa; IQR, 5.4–10.9) and genotype 2 (6.7 kPa; IQR, 4.9–8.8) ($p = 0.02$).

Overall, 59 (16%) met the criteria of cirrhosis (TE>17.1 kPa), and 132 (36%) had fibrosis (Table 1).

For genotype 1 and 2, TE values did not differ according to *IL28B* genotype. For genotype 3, patients with the *IL28B* CC genotype had significantly higher TE values (10.0 kPa; 6.2–16.8) than patients with TC (7.6 kPa; 5.7–14.3) or TT (5.6 kPa; 4.7–7.7) ($P = 0.04$, Table 2).

Factors associated with advanced fibrosis (TE>9.5 kPa)

By univariate logistic regression analysis, increasing age, ALT and HCV genotype 3 were each associated with advanced liver fibrosis (TE>9.5 kPa) whereas sex, race, route of exposure, duration of known seropositivity, viral load, *IL28B* genotypes or center were not. In multivariate analysis, increasing age (OR 1.08 (95% CI, 1.05–1.12) per year increment), ALT (OR 1.01 (95% CI,1.004–1.012) per unit increment) and HCV genotype 3 compared to genotype 1 (OR 1.91 (95% CI, 1.10–3.33) remained statistically significantly associated with advanced liver fibrosis. There was a trend towards less liver stiffness for genotype 2 compared to genotype 1 (OR 0.47 (95% CI, 0.17–1.30).

In genotype 3 patients, the *IL28B* CC genotype was associated with a two-fold increased risk of advanced liver fibrosis in the unadjusted analysis (OR 2.09, 95%

Table 2. Association between HCV genotype, *IL28B* genotype and results of transient elastography for 369 patients with chronic hepatitis C virus infection.

IL28B genotype	HCV genotype 1, (n=185)				HCV genotype 2, (n=35)				HCV genotype 3, (n=149)			
	CC (n=48)	TC (n=106)	TT (n=23)	p-value	CC (n=19)	TC (n=10)	TT (n=5)	p-value	CC (n=62)	TC (n=67)	TT (n=10)	p-value
Transient Elastography, kPa (IQR)	6.9 (5.4–11.1)	7.4 (5.3–11.9)	8.1 (6.4–11.9)	0.61[***]	7.1 (5.8–10.0)	5.9 (4.7–6.3)	7.6 (7.5–7.8)	0.22[***]	10.0 (6.2–16.8)	7.6 (5.7–14.3)	5.6 (4.7–7.7)	0.04[***]
Liver stiffness stage				0.78[*]				0.12[*]				0.26[*]
No fibrosis (≤7.1 kPa)	25 (52)	52 (49)	10 (43)		10 (53)	8 (80)	1 (20)		23 (37)	32 (48)	7 (70)	
Fibrosis (7.1–17.1 kPa)	18 (38)	40 (38)	8 (35)		7 (37)	1 (10)	4 (80)		24 (39)	21 (31)	3 (30)	
Cirrhosis (>17.1 kPa)	5 (10)	14 (13)	(22)		2(10)	1 (10)	0 (0)		15 (24)	14 (21)	0 (0)	

*Fisher's exact test, **x^2 or ***kruskall-wallis applied as appropriate. All values are median and interquartile range.

doi:10.1371/journal.pone.0115882.t002

CI 1.05–4.85)) compared to the CT/TT genotype. In multivariate analysis adjusted for age and ALT this association remained but lost statistical significance (OR 1.58, 95% CI 0.66–3.75).

For HCV genotype 1 (OR 0.78, 95% CI, 0.33–1.86) and genotype 2 (OR 2.13, 95% CI, 0.32–14.08) there was no association between *IL28B* genotype and advanced liver fibrosis.

Factors associated with cirrhosis (TE>17.1 kPa)

By univariate logistic regression analysis, increasing age, ALT and HCV genotype 3 were each associated with cirrhosis (TE>17.1 kPa) whereas sex, race, route of exposure, duration of known seropositivity, *IL28B* genotypes or center were not (table 3). In multivariate analysis, increasing age, ALT and HCV genotype 3 compared to genotype 1 remained statistically significantly associated with cirrhosis (table 3).

After stratification for HCV genotype, there was no association between *IL28B* CC genotype and cirrhosis for any HCV genotype.

All analyses involving *IL28B* were repeated separately for Caucasians in order to account for race specific effects but did not alter the results (data not shown).

Discussion

In this cross-sectional study of patients infected with HCV, increasing age and HCV genotype 3 were associated with increased liver stiffness, while the *IL28B* CC genotype was not. Steatosis associated with HCV genotype 3 infection is a known risk factor for fibrosis [33], and the presence of steatosis in HCV genotype 3 infection is associated with higher HCV RNA viral load compared to other genotypes [34–36]. Several studies suggest that HCV replication could be enhanced in patients carrying the *IL28B* C allele [11, 37, 38]. It has been hypothesised that patients with HCV genotype 1 infection have "metabolic

Table 3. Predictors of liver cirrhosis (liver stiffness >17.1 kPa).

	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	P value
Age, per year increment	1.08 (1.05–1.12)	1.09 (1.05–1.13)	<0.0001
Sex		-	
Male	1.0		
Female	0.81 (0.45–1.46)		
Route of exposure		-	
Other	1.0		
IDU	0.87 (0.50–1.53)		
Race		-	
Caucasian	1.0		
Other	0.60 (0.27–1.33)		
Time with HCV, per year increment	1.04 (0.98–1.09)	-	
1st HCV RNA, log$_{10}$ IU/mL	0.75 (0.55–1.04)	-	
ALT	1.01 (1.00–1.01)	1.01 (1.00–1.01)	0.002
Center		-	
Odense University Hospital	1.0		
Hvidovre Hospital	0.90 (0.50–1.61)		
HCV genotype			0.01
1	1.0	1.0	
2	0.63 (0.18–2.21)	0.47 (0.11–1.99)	
3	1.84 (1.03–3.28)	2.55 (1.23–5.31)	
***IL28B* genotype**		-	
TT/CT	1.0		
CC	1.13 (0.63–2.03)		

doi:10.1371/journal.pone.0115882.t003

steatosis'', and HCV genotype 3 infected have ''viral steatosis'' [34, 39]. The mechanisms underlying viral steatosis caused by HCV genotype 3 are not fully elucidated.

Overall steatosis is an important cofactor in accelerating the development of hepatic fibrosis and necroinflammatory activity in patients with CHC [35]. This corresponds well with our findings of an increased risk of fibrosis in patients infected with HCV genotype 3.

For genotype 3, the *IL28B* CC genotype was associated with a higher TE value in univariate analysis. This association lost significance in multivariate analysis when adjusted for ALT and age. For HCV infected patients with elevated ALT it should be noted that inflammation of the liver is considered a confounding variable in analysis of liver stiffness [40]. ALT was not associated with *IL28B* genetic variants.

Barreira et al. showed that the *IL28B* CC genotype was associated with cirrhosis using a TE cut-off of 14.5 kPa [14]. By liver biopsy, Rembeck et al. showed that the CC genotype in HCV genotype 3 mono-infected patients entailed more pronounced portal inflammation and steatosis [16]. Similarly Ydreborg et al.

reported that the CC SNP was associated with a higher TE value in HCV genotype 3 infected patients [17].

These mentioned studies differ from our study in several aspects. In the study of Barreiro et al. 86% were infected through IDU compared to 60% in our population, whereas HCV was transmitted through IDU in fewer patients in the study of Ydreborg et al. [14, 17]. Due to sample size, we might lack statistical power in our study.

Other studies have assessed liver fibrosis by liver biopsy, whereas we used TE. TE is known to be a valid tool for estimating fibrosis but liver biopsy is still considered the gold standard [30]. A recent study by Degos et al. suggested that TE and liver biopsy performed comparable with regard to a diagnosis of cirrhosis whereas liver biopsy was superior in diagnosing fibrosis [31].

Various transient elastography cut-off values to define fibrosis and cirrhosis have been suggested [29–31]. We evaluated two of these. Using either of these, HCV genotype, ALT and age consistently were associated with fibrosis and cirrhosis, whereas the *IL28B* CC genotype only was not.

Further studies of a possible role of *IL28B* and other genetic variants in the development of fibrosis and cirrhosis are warranted.

Stengths of our study include the evaluation in two centers, and that we have a comparable number of HCV genotype 1 and 3 infected patients. Some limitations in our study must be acknowledged. First, TE is an indirect marker of liver fibrosis and several factors - most importantly elevated ALT - may overestimate fibrosis when determined by TE. Second, due to the retrospective design it was not possible to obtain information about certain potential confounding factors e.g. alcohol consumption among our patients. Third, it was not possible to estimate the exact duration of infection with HCV, which may explain the lack of an association between length of infection and cirrhosis. Most of our patients were diagnosed with HCV in their forties, but the vast majority has been infected years before detection. Genotype 3 infected patients had a median duration of known infection that was about twice as long as genotype 1 infected patients. However, this did not affect the results in the adjusted analysis. Fourth, the small numbers of carriers of the *IL28B* TT genotype infected with HCV genotype 3 restricted the comparison of the three *IL28B* genotypes separately.

In conclusion this two-center study evaluated the association of *IL28B* genotypes and the severity of liver fibrosis in HCV infected patients. We described a possible association of increased liver stiffness with HCV genotype 3 infection. Genetic variation in *IL28B* may influence fibrosis development in HCV genotype 3 infected individuals but further studies are required to confirm this.

Acknowledgments

Author Contributions

Conceived and designed the experiments: LFL LNC TB. Analyzed the data: LFL LNC PBC TB. Contributed reagents/materials/analysis tools: KS. Drafting of the manuscript: LFL LNC TB. Critical revision of the manuscript for important intellectual content: LFL LNC TB LR NW KS PBC. Acquisition of data: LFL NW LR KS PBC TB. Study supervision: TB PBC.

References

1. **WHO | Hepatitis C (n.d.)**.WHO. Available: http://www.who.int/mediacentre/factsheets/fs164/en/index.html.

2. **Hansen N, Obel N, Christensen PB, Krarup H, Laursen AL, et al.** (2009) Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. Journal of Viral Hepatitis 16: 659–665. doi:10.1111/j.1365-2893.2009.01126.x.

3. **Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, et al.** (2007) Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology 46: 1350–1356. doi:10.1002/hep.21826.

4. **Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA** (1997) The Association between Hepatitis C Virus Genotype and Human Immunodeficiency Virus Disease Progression in a Cohort of Hemophilic Men. J Infect Dis 175: 164–167. doi:10.1093/infdis/175.1.164.

5. **Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA** (2000) The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47: 845–851. doi:10.1136/gut.47.6.845.

6. **Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, et al.** (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 51: 655–666. doi:10.1016/j.jhep.2009.05.016.

7. **Probst A, Dang T, Bochud M, Egger M, Negro F, et al.** (2011) Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. Journal of Viral Hepatitis 18: 745–759.

8. **Barreiro P, Martín-Carbonero L, Núñez M, Rivas P, Morente A, et al.** (2006) Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. Clin Infect Dis 42: 1032–1039. doi:10.1086/501021.

9. **Ahmed MM, Mutimer DJ, Martin B, Elias E, Wilde JT** (1999) Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders. Haemophilia 5: 49–55.

10. **Poynard T, Bedossa P, Opolon P** (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet 349: 825–832. doi:10.1016/S0140-6736(96)07642-8.

11. **Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al.** (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401. doi:10.1038/nature08309.

12. **Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al.** (2010) Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology 138: 1338–1345.e7. doi:10.1053/j.gastro.2009.12.056.

13. **Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al.** (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801. doi:10.1038/nature08463.

14. **Barreiro P, Pineda JA, Rallón N, Naggie S, Martín-Carbonero L, et al.** (2011) Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients Receiving Antiretroviral Therapy. J Infect Dis 203: 1629–1636. doi:10.1093/infdis/jir113.

15. **Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, et al.** (2011) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54: 1127–1134. doi:10.1002/hep.24503.

16. **Rembeck K, Alsiö A, Christensen PB, Färkkilä M, Langeland N, et al.** (2012) Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 7: e29370. doi:10.1371/journal.pone.0029370.

17. **Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, et al.** (2013) Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection. PLoS One 8: e80172. doi: 10.1371/journal.pone.0080172.

18. **Noureddin M, Wright EC, Alter H, Clark S, Thomas E, et al.** (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology: n/a – n/a. doi:10.1002/hep.26506.

19. **Cai T, Dufour J-F, Muellhaupt B, Gerlach T, Heim M, et al.** (2011) Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 55: 529–535. doi:10.1016/j.jhep.2010.12.020.

20. **Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, et al.** (2011) Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 55: 1195–1200. doi:10.1016/j.jhep.2011.03.015.

21. **Clausen LN, Weis N, Schønning K, Fenger M, Krarup H, et al.** (2011) Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort. Scand J Infect Dis 43: 798–803. doi:10.3109/00365548.2011.589077.

22. **Krarup HB, Drewes AM, Madsen PH** (1998) A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 58: 415–422.

23. **Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, et al.** (2008) Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 80: 254–260. doi:10.1002/jmv.21073.

24. **Krarup HB, Møller JM, Christensen PB, Fuglsang T, Ingerslev J, et al.** (2000) Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 7: 435–439.

25. **Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, et al.** (2007) Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region Sequences. J Clin Microbiol 45: 1102–1112. doi:10.1128/JCM.02366-06.

26. **Clausen LN, Astvad K, Ladelund S, Larsen MV, Schønning K, et al.** (2012) Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS 26: 1509–1516. doi:10.1097/QAD.0b013e3283553581.

27. **Nijman IJ, Kuipers S, Verheul M, Guryev V, Cuppen E** (2008) A genome-wide SNP panel for mapping and association studies in the rat. BMC Genomics 9: 95. doi:10.1186/1471-2164-9-95.

28. **Castera L, Forns X, Alberti A** (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835–847. doi:10.1016/j.jhep.2008.02.008.

29. **Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al.** (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128: 343–350. doi:10.1053/j.gastro.2004.11.018.

30. **Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, et al.** (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41: 48–54. doi:10.1002/hep.20506.

31. **Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, et al.** (2010) Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). Journal of Hepatology 53: 1013–1021. doi:10.1016/j.jhep.2010.05.035.

32. **Rodriguez S, Gaunt TR, Day INM** (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505–514. doi:10.1093/aje/kwn359.

33. **Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R** (2002) Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37: 837–842.

34. **Asselah T, Rubbia-Brandt L, Marcellin P, Negro F** (2006) Steatosis in chronic hepatitis C: why does it really matter? Gut 55: 123–130. doi:10.1136/gut.2005.069757.

35. **Adinolfi LE, Gambardella M, Andreana A, Tripodi M, Utili R, et al.** (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358–1364. doi:10.1053/jhep.2001.24432.

36. **Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, et al.** (2007) Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. Journal of Viral Hepatitis 14: 29–35. doi:10.1111/j.1365-2893.2006.00777.x.

37. **Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, et al.** (2011) Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 25: 761–766. doi:10.1097/QAD.0b013e32834488e7.

38. **McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al.** (2010) Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology 138: 2307–2314. doi:10.1053/j.gastro.2010.02.009.

39. **Petit J-M, Bour J-B, Galland-Jos C, Minello A, Verges B, et al.** (2001) Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. Journal of Hepatology 35: 279–283. doi:10.1016/S0168-8278(01)00143-X.

40. **Tapper EB, Cohen EB, Patel K, Bacon B, Gordon S, et al.** (2012) Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients with Chronic HCV Infection. Clin Gastroenterol Hepatol 10: 932–937.e1. doi:10.1016/j.cgh.2012.01.015.